Relypsa (RLYP) Given Daily Coverage Optimism Score of 0.20

News articles about Relypsa (NASDAQ:RLYP) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Relypsa earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 44.0155941927307 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of Relypsa (RLYP) traded down $0.01 during trading on Monday, hitting $31.98. 107 shares of the stock traded hands, compared to its average volume of 2,933,219. Relypsa has a 1-year low of $10.26 and a 1-year high of $32.12.

TRADEMARK VIOLATION WARNING: “Relypsa (RLYP) Given Daily Coverage Optimism Score of 0.20” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.com-unik.info/2017/12/18/relypsa-rlyp-given-daily-coverage-optimism-score-of-0-20.html.

Relypsa Company Profile

Relypsa, Inc is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company’s technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address.

Insider Buying and Selling by Quarter for Relypsa (NASDAQ:RLYP)

What are top analysts saying about Relypsa? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Relypsa and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit